Drug Trial Radar · NCT03365609
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,440
Planned (sponsor's estimate)
Start
Sep 20, 2017
Primary completion
Oct 1, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Ying HUANGAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangzhou Women and Children's Medical Center; The Children's Hospital of Zhejiang University School of Medicine; Beijing Children's Hospital; Tang-Du Hospital
- First posted
- Dec 7, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With the resistance of Helicobacter pylori increasing, low and unsatisfactory eradication rate (64%) have been observed with standard triple therapy in European children. Which regimen is appropriate for Chinese children? There is no large scale, multi center studies in China about treatment, CYP2C19 gene polymorphism, resistance rate and resistance genotype. Investigators want to perform a research to compare four different treatment regimens(triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy)as the first-line treatment of Helicobacter pylori in Chinese children and investigation of resistance, impact factors and changes of microbiota after the therapy. The results of the study will provide theoretical basis to make the new guideline of diagnosis and therapy of Helicobacter pylori in Chinese children. It advance instruct and norm the clinical practice for Chinese pediatrician to increase the cure rate of Helicobacter pylori and decrease the resistance.
Conditions
- Helicobacter Infections
Interventions
triple therapyDrug
Omeprazole+Amoxicillin+Clarithromycin
sequential therapyDrug
the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
bismuth quadruple therapyDrug
Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
concomitant therapyDrug
Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- 13C-UBTTime frame: 13C-UBT was assessed at 4-6 weeks after completion of therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's hospital of Fudan university
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.